IN RE Talis Biomedical Securities Litigation

  1. October 01, 2024

    Biotech Investors Reach $32.5M Deal Over Failed COVID Test

    A class of Talis Biomedical Corp. investors accusing the company of inflating their stock price in the run-up to its IPO and then failing to launch a COVID-19 diagnostic test asked a California federal judge on Monday to preliminarily approve their $32.5 million settlement, citing Talis' shrinking cash reserves and imminent plans to file for bankruptcy.

  2. February 12, 2024

    Investors Win Class Cert. Against Failed COVID Test Maker

    Investors suing biotech company Talis Biomedical Corp. have received class certification in a suit alleging the company hurt investors when trading prices sank a month after its initial public offering when the company failed to secure U.S. Food and Drug Administration approval for its flagship testing platform.

  3. October 16, 2023

    Investors In Maker Of Failed COVID Test Want Class Certified

    A group of investors suing a biotech company that failed to launch a COVID-19 diagnostic test promoted in the run-up to the firm's IPO urged a California federal court to certify a class, arguing the move is called for because the number of affected shareholders is large and damages are likely too small for individual litigation.

  4. May 01, 2023

    Biotech Co. To Face Amended Investor Suit Over COVID Test

    A California federal judge has declined to dismiss an amended investor complaint against a biotech company over issues with its COVID-19 test rollout, holding the revised suit plausibly alleges the defendants made false and misleading statements.

  5. December 12, 2022

    Biotech Co. Gets Investor Suit Over Failed COVID Test Tossed

    A biotech company that was sued by investors over issues with its COVID-19 test rollout convinced a California federal judge to toss the suit after arguing that none of the statements identified by the plaintiffs in the complaint were false or misleading when made.